Endothelial Prostacyclin Release in Systemic Lupus Erythematosus

Stephen B Coade; Els van Haaren; S Loizou; Mark J Walport; A Michael Denman; Jeremy D Pearson

doi:10.1055/s-0038-1646534

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1989; 61(01): 097-100
DOI: 10.1055/s-0038-1646534

Original Article

Schattauer GmbH Stuttgart

Endothelial Prostacyclin Release in Systemic Lupus Erythematosus

Stephen B Coade

¹The Section of Vascular Biology, MRC Clinical Research Centre, Harrow, Middx, UK

,

Els van Haaren

¹The Section of Vascular Biology, MRC Clinical Research Centre, Harrow, Middx, UK

,

S Loizou

³The Department of Medicine, Royal Postgraduate Medical School, Hammersmith, London, UK

,

Mark J Walport

³The Department of Medicine, Royal Postgraduate Medical School, Hammersmith, London, UK

,

A Michael Denman

²The Division of Rheumatology, MRC Clinical Research Centre, Harrow, Middx, UK

,

Jeremy D Pearson

¹The Section of Vascular Biology, MRC Clinical Research Centre, Harrow, Middx, UK

› Institutsangaben

Abstract

als PDF herunterladen

Summary

The ability of sera from patients with SLE to stimulate endothelial cell prostacyclin production was studied using a standardized assay system for testing the effects of serum on cultured human endothelial cell monolayers. The effects of 20 normal and 32 SLE sera on endothelial prostacyclin production were measured. No differences between the rates of prostacyclin production were seen between the two groups, either basally or when prostacyclin release was stimulated with thrombin or bradykinin. In the SLE samples there was no correlation between anticardiolipin IgG or IgM titres and their ability to stimulate basal or agonist-induced prostacyclin release. These results suggest that the elevated risk of thrombosis in SLE patients is not associated with inhibition of endothelial cell prostacyclin synthesis.

Keywords

SLE - Prostacyclin - Endothelium - Lupus anticoagulant - Anticardiolipin antibodies

PDF (249 kb)

Referenzen

References
1 Bowie EJ W, Thompson JH, Pascuzzi CA, Owen CA. Thrombosis in SLE despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-430
2 Byron MA. The clotting defect in SLE. Clin Rheum Dis 1982; 8: 137-51
3 Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GR V. Thrombosis in systemic lupus erythematosus: striking assoca- tion with the presence of circulating lupus anticoagulant. Br Med J 1983; 287: 1021-1023
4 Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 1980; 92: 156-9
5 Gastineau DA, Kazmier FJ, Nichols WL, Bowie EJ W. Lupus anticoagulant: An analysis of the clinical and laboratory features of 219 cases. Am J Hematol 1985; 19: 265-275
6 Shapiro SS, Thiagarajan P. Lupus anticoagulants. In: Progress in Hemostasis and Thrombosis. Spaet TH. (ed) Grune and Stratton; Orlando, FL: 1982. 6 263-285
7 Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CB, Harris EN. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738-745
8 McVerry BA, Machin SJ, Parry H, Goldstone AH. Reduced prostacyclin activity in systemic lupus erythematosus. Ann Rheum Dis 1980; 39: 524-525
9 Carreras LO, Defreyn G, Machin SJ, Vermylen J, Deman R, Spitz B, Van Assche A. Arterial thrombosis, intrauterine death and “lupus” anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; 1: 244-246
10 Marchesi D, Parbtani A, Frampton G, Livio M, Remuzzi G, Cameron JS. Thrombotic tendency in systemic lupus erythematosus. Lancet 1981; 1: 719
11 Carreras LO, Vermylen JG. “Lupus” anticoagulant and thrombosis – possible role of inhibition of prostacyclin formation. Thromb Haemostas 1982; 48: 38-40
12 Elias M, Eldor A. Thromboembolism in patients with the “lupus”-type circulating anticoagulant. Arch Intern Med 1984; 144: 510-515
13 Schorer AE, Watson KV. The “Lupus Anticoagulant” induces functional changes in endothelial cells and platelets. Thromb Haemostas 1987; 58: 232 (Abstr)
14 Hasselaar P, Derksen RH W M, Blokzijl L, de Groot PG. Thrombosis associated with antiphospholipid antibodies cannot be explained by effects on endothelial and platelet prostanoid synthesis. Thromb Haemostas 1988; 59: 80-85
15 Rustin MH A, Bull HA, Machin SJ, Isenberg DA, Snaith ML, Dowd PM. Effects of the lupus anticoagulant in patients with systemic lupus erythematosus on endothelial cell prostacyclin release and procoagulant activity. J Invest Dermatol 1988; 90: 744-748
16 Petraiuolo W, Bovill E, Hoak J. The lupus anticoagulant does not inhibit the release of prostacyclin from human endothelial cells. Thromb Haemostas. 1987 58. 390. (Abstr)
17 Tan EM, Cohen AS, Fries JF. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277
18 Hollingsworth P, De Vere Tyndall A, Ansell BM, Platts-Mills T, Gumpel JM, Meretin J, Smith DS, Denman AM. Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases. Ann Rheum Dis 1982; 41: 557-562
19 Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria J Clin Invest 1973; 52: 2745-2756
20 Ager A, Gordon JL, Moncada S, Pearson JD, Salmon JA, Trevethick MA. Effects of isolation and culture on prostaglandin synthesis by aortic endothelial and smooth muscle cells. J Cell Physiol 1982; 110: 9-16
21 Nilsson IM, Astedt B, Hedner U, Berezin D. Intrauterine death and circulating anticoagulant (“antithromboplastin”). Acta Med Scand 1975; 197: 153-159
22 Hughes GR V. Connective Tissue Diseases. 3rd. ed Blackwell, Oxford; 1987. Chs. 2 and 3
23 Lechner K. Lupus anticoagulants and thrombosis. In: Thrombosis and Haemostasis 1987. Verstraete M. et al. (eds) Leuven University Press; Leuven: 1987. pp 525-547
24 Freyssinet J-M, Wiesel M-L, Gauchy J, Boneu B, Cazenave J-P. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity - a mechanism for thrombosis. Thromb Haemostas 1986; 55: 309-313
25 Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-1352
26 Owen WG. Interactions of thrombin, antithrombin III and Protein C with endothelium. In: Biology of Endothelial Cells. Jaffe EA. (ed) Martinus Nijhoff; The Hague: 1983. pp 259-267
27 Asherson RA, Harris EN, Hughes GR V, Ritter JM, Barrow SE, Jones M. Prostacyclin in systemic lupus and anti-cardiolipin syndrome. Ann Rheum Dis 1987; 47: 422-424
28 Comp PC, De Bault LE, Esmon NL, Esmon CT. Human thrombomodulin is inhibited by IgG from two patients with nonspecific anticoagulants. Blood 1983; 62 Suppl (Suppl. 01) 299a
29 Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 1986; 314: 1193-1194
30 Cines DB, Lyss AP, Reeber M, Bina M, DeHoratius RJ. Presence of complement fixing anti-endothelial cell antibodies in SLE. J Clin Invest 1984; 73: 611-625
31 Le Roux G, Wautier M-P, Guillevin L, Wautier J-L. IgG binding to endothelial cells in systemic lupus erythematosus. Thromb Haemostas 1986; 56: 144-146
32 Rosenbaum J, Pottinger BE, Loizou S, Woo P, Black CM, Byron MA, Pearson JD. Autoantibodies to endothelial cells in connective tissue diseases. Clin Exp Immunol 1988; 72: 450-456
33 Tannenbaum SH, Finko R, Cines DB. Antibody and immune complexes induce tissue factor prodution by human endothelial cells. J Immunol 1986; 137: 1532-1537